We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
AbbVie is seeking EMA marketing authorization for epcoritamab for treating patients with relapsed/refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. Read More
The FDA has declined to green-light Gilead Sciences’ hepatitis delta virus (HDV) drug bulevirtide because of manufacturing and delivery concerns, meaning there will continue to be no approved treatment for the condition in the U.S. Read More